Celcuity (NASDAQ: CELC) stock surged 12.62% in pre-market trading on Monday, July 14, 2025, reaching $15.35 after securing patent on gedatolisib dosing exclusivity through 2042. This marks a significant jump from the previous closing price of $13.63 recorded on the prior trading day.
Celcuity Inc. (CELC) has secured U.S. Patent No. 12,350,276, protecting the clinical dosing regimen of its lead drug candidate, gedatolisib, for ER+/HER2- breast cancer patients. This patent extends Celcuity’s exclusivity in the U.S. through 2042.
